Literature DB >> 24463401

HPLC-UV analysis of thymidine and deoxyuridine in plasma of patients with thymidine phosphorylase deficiency.

Susan Mohamed1, Leonardo Caporali1, Roberto De Giorgio2, Valerio Carelli3, Manuela Contin4.   

Abstract

We present a simple, fast and validated method for the determination of the two nucleosides thymidine (dThd) and deoxyuridine (dUrd) in plasma of patients with symptoms suggestive of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), using high performance liquid chromatography coupled with ultraviolet spectrophotometric detection (HPLC-UV). Plasma sample (100μL) pretreatment was based on simple deproteinization by 1.2M perchloric acid, using theophylline as internal standard (I.S.). HPLC-UV analysis was carried out on a Synergi 4μm Hydro-RP, 150×4mm I.D. column, at room temperature. The mobile phase was a mixture of potassium dihydrogen phosphate buffer (20mM, pH 4.5) and acetonitrile (95:5, v/v), at an isocratic flow rate of 0.7mL/min. The UV detector was set at 267nm. The chromatographic run lasted 19min. Similar pyrimidine nucleotides and nucleosides do not interfere with the assay. Calibration curves were linear for both dThd and dUrd over a range of 0.5 to 5.0μg/mL. The limit of quantitation was 0.5μg/mL for both nucleosides and the absolute recovery was >90% for dThd, dUrd and the I.S. Both intra- and inter-assay precision and accuracy were lower than 10% at all tested concentrations. The proposed method was successfully applied to measure plasma concentrations of dThd and dUrd in two MNGIE patients. This assay simplifies both plasma pretreatment and chromatographic conditions of previously reported procedures and describes the first validated method for the determination of the two nucleotides in human plasma.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Deoxyuridine; High performance liquid chromatography; Mitochondrial neurogastrointestinal encephalomyopathy; Thymidine; UV detection

Mesh:

Substances:

Year:  2014        PMID: 24463401     DOI: 10.1016/j.jchromb.2014.01.003

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

Review 1.  Mitochondrial Neurogastrointestinal Encephalomyopathy: Into the Fourth Decade, What We Have Learned So Far.

Authors:  Dario Pacitti; Michelle Levene; Caterina Garone; Niranjanan Nirmalananthan; Bridget E Bax
Journal:  Front Genet       Date:  2018-12-21       Impact factor: 4.599

Review 2.  Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network.

Authors:  Michio Hirano; Valerio Carelli; Roberto De Giorgio; Loris Pironi; Anna Accarino; Giovanna Cenacchi; Roberto D'Alessandro; Massimiliano Filosto; Ramon Martí; Francesco Nonino; Antonio Daniele Pinna; Elisa Baldin; Bridget Elizabeth Bax; Alessio Bolletta; Riccardo Bolletta; Elisa Boschetti; Matteo Cescon; Roberto D'Angelo; Maria Teresa Dotti; Carla Giordano; Laura Ludovica Gramegna; Michelle Levene; Raffaele Lodi; Hanna Mandel; Maria Cristina Morelli; Olimpia Musumeci; Alessia Pugliese; Mauro Scarpelli; Antonio Siniscalchi; Antonella Spinazzola; Galit Tal; Javier Torres-Torronteras; Luca Vignatelli; Irina Zaidman; Heinz Zoller; Rita Rinaldi; Massimo Zeviani
Journal:  J Inherit Metab Dis       Date:  2020-09-08       Impact factor: 4.750

3.  Mitochondrial neurogastrointestinal encephalomyopathy: approaches to diagnosis and treatment.

Authors:  Bridget E Bax
Journal:  J Transl Genet Genom       Date:  2020-03-30

4.  Quantification of Plasma and Urine Thymidine and 2'-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy.

Authors:  Karin Kipper; Max Hecht; Natalicia J Antunes; Lynette D Fairbanks; Michelle Levene; Sema Kalkan Uçar; Andrew Schaefer; Emma L Blakely; Bridget E Bax
Journal:  J Clin Med       Date:  2020-03-13       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.